MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

NCT02536794 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Estrogen Receptor Negative
Estrogen Receptor Positive
HER2/Neu Negative
Recurrent Breast Carcinoma
Stage IV Breast Cancer

Interventions

BIOLOGICAL: Anti-B7H1 Monoclonal Antibody MEDI4736
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
BIOLOGICAL: Tremelimumab

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]